Compare GRRR & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRRR | PRME |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.7M | 553.2M |
| IPO Year | 2022 | 2022 |
| Metric | GRRR | PRME |
|---|---|---|
| Price | $14.50 | $3.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 816.8K | ★ 2.5M |
| Earning Date | 06-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $69.35 | $7.06 |
| Revenue Next Year | $85.38 | $47.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $9.04 | $2.67 |
| 52 Week High | $23.49 | $6.94 |
| Indicator | GRRR | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 51.61 |
| Support Level | $13.46 | $3.14 |
| Resistance Level | $16.18 | $3.72 |
| Average True Range (ATR) | 0.62 | 0.22 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 50.65 | 45.70 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments. Its expertise lies in revolutionizing urban operations, enhancing security, and optimizing digital transformation. It delivers pioneering products that integrate AI, deep learning, and edge computing to advance intelligent video surveillance, facial recognition, license plate recognition, post-event analytics, cybersecurity, and network intelligence.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.